Rare diseases
Investigational molecules
Locations
Back to Belgium47 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury
BelgiumStudy of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment
BelgiumStudy Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BelgiumStudy of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
BelgiumStudy of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer
BelgiumStudy Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma
BelgiumStudy of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma
BelgiumStudy on Aspirin for Preventing Recurrence and Improving Survival in Patients with Resected Colon Cancer
BelgiumStudy of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels
BelgiumStudy on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction
BelgiumStudy on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.
This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
